image credit- shutterstock
Taiwan based Lotus Pharmaceutical has entered into an agreement to acquire Sandoz AG’s Philippines business. Subject to closing conditions, the acquisition is expected to be completed in Q2 2026.
Upon completion, Lotus will undertake the sales and marketing of existing products of Sandoz Philippines. The acquired portfolio is primarily focused on generics and biosimilars, covering a broad range of therapeutic areas, including cardiovascular (~40%), oncology (~25%), anti-infectives (~10%), and other categories. The business will provide Lotus a strong and established platform in one of Southeast Asia’s fastest-growing pharmaceutical markets.
Following the acquisition, approximately 80 employees from Sandoz Philippines are expected to join Lotus, significantly strengthening the Company’s local commercial capabilities and expanding its footprint across hospital and specialty care channels in the Philippines.
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceuticals, commented: " This acquisition represents another important step in Lotus’ strategy to expand its presence across Southeast Asia and reinforce our position in high-value generics and biosimilars. By integrating Sandoz’s Philippines business into our operations, we will gain a scaled commercial platform, a diversified therapeutic portfolio, and a talented local team. This transaction aligns with our long-term ambition to build a leading global pharmaceutical company while improving patient access to quality medicines."
